The mission of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the United States Food and Drug Administration (FDA) is to identify, prioritize, sponsor, coordinate, and promote innovative activities — with a special interest in optimizing clinical trials — that will expedite the discovery and development of improved analgesic, anesthetic, and addiction treatments for the benefit of the public health.

ACTTION is a multi-year, multi-phase initiative that is closely aligned with the FDA's Critical Path Initiative. This public-private partnership has been designed to streamline the discovery and development process for new analgesic, anesthetic, and addiction medications and to more generally accelerate the development of treatments with improved efficacy and safety.

The key objectives of ACTTION involve initiating and supporting strategic collaborations among a broad spectrum of stakeholders — including, but not limited to, academia, the FDA and other government agencies, industry, professional organizations, patient advocacy groups, foundations, and philanthropic organizations — with the goals of sharing data and innovative thinking about the development of novel therapeutics. These strategic collaborations involve a wide range of research projects and other activities, for example, scientific workshops, consensus meetings, and in-depth analyses of clinical trial data to determine the effects of research methods on study assay sensitivity and efficiency.

ACTTION is intended to have benefits that are international in scope. To represent the bridges that ACTTION is establishing among its diverse stakeholders, this website is illustrated with watermarks of two bridges that share the distinction of connecting different continents. Directly below is the First Bosphorus Bridge in Istanbul, Turkey, which connects Europe and Asia; on the Contact Us webpage is the Leifur Eiriksson Bridge in Iceland's Reykjanes peninsula, which spans a rift valley between the North American and European continental plates.


September 30, 2014: Bob Rappaport, MD, Retires from FDA and Will Receive APS Bonica Award

Bob A. Rappaport, MD, Director of FDA’s Division of Anesthesia, Analgesia, and Addiction Products for the past 11 years, has retired. The ACTTION pubic-private partnership was Dr. Rappaport’s idea, and he has been an invaluable collaborator and source of inspiration, ideas, and energy for all of its activities since its inception. ACTTION is therefore very pleased to announce that Dr. Rappaport will receive the 2015 John & Emma Bonica Public Service Award from the American Pain Society, which honors outstanding contributions to the field of pain through public education, public service, and other efforts to further knowledge about pain. There can be no better summary of Dr. Rappaport’s exceptional contributions to the FDA and the field of pain than Dr. Janet Woodcock’s message to the staff of FDA’s Center for Drug Evaluation and Research, available here.

September 3, 2014: ACTTION Presentations at the 15th World Congress on Pain

ACTTION will be well represented at the 15th World Congress on Pain, being held in Buenos Aires from October 6-11, 2014. Paul Desjardins, DMD, PhD, a member of ACTTION's Executive Committee, will give a talk on "The Actions of ACTTION and the Impact of IMMPACT" at the Acute Pain Special Interest Group (SIG) Satellite Meeting; the satellite meeting was organized by Daniel Carr, MD, Chair of the Acute Pain SIG, and Co-Chair of ACTTION’s Board of Advisors and a member of its Executive Committee. Jennifer Gewandter, PhD, will present a poster on "Data Interpretation in Analgesic Clinical Trials with Statistically Non-significant Primary Analyses: An ACTTION Systematic Review" (with co-authors A. McKeown, S. Smith, M. McDermott, M. Hunsinger, M. Williams, M. Rowbotham, D. Turk, R. Dworkin). Shannon Smith, PhD, ACTTION’s Assistant Director, will give a talk on "Phase 2 and 3 Clinical Trials" at a symposium on "Improving and Accelerating the Development of New Drugs for Neuropathic Pain."